Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06088472

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Grit Biotechnology · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.

Conditions

Interventions

TypeNameDescription
BIOLOGICALTIL injectionAutologous tumor infiltrating lymphocyte injection

Timeline

Start date
2021-04-21
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2023-10-18
Last updated
2025-09-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06088472. Inclusion in this directory is not an endorsement.

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors (NCT06088472) · Clinical Trials Directory